It had been well documented that AIB1 promotes cancer initiation, proliferation, tumorigenesis, invasion, and metastasis both in breast and prostate cancer, and that high expression of AIB1 was closely associated with an ascending clinical stage and/or poor patient prognosis in these two hormone-sensitive malignancies 15-19. Here, NCOA3 is linked to prostate carcinoma.